Method for the treatment or prevention of infection-related immune conditions using a composition comprising igm

Abstract

Embodiments of the present invention provide methods for the treatment or prevention of infection-related immune conditions using compositions comprising IgM.

1 - 26 . (canceled) 
     
     
         27 . A pharmaceutical composition for the treatment of sepsis, comprising:
 a composition suitable for injection comprising immunoglobulin in a pharmaceutically acceptable carrier, wherein the immunoglobulin is at least 90% IgM.   
     
     
         28 . The composition according to  claim 27 , characterized in that sepsis is produced by  Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pneumoniae, Clostridium difficile, Clostridium botulinum , or combinations thereof. 
     
     
         29 . The composition according to  claim 27 , characterized in that treatment of sepsis is performed through immunomodulation. 
     
     
         30 . The composition according to  claim 29 , characterized in that immunomodulation is performed through inhibition of NF-κB induction, through the inhibition of proliferation of peripheral blood mononuclear cells or combination thereof. 
     
     
         31 . (canceled) 
     
     
         32 . The composition according to  claim 27 , characterized in that the composition has a 95% (w/v) of IgM purity. 
     
     
         33 . The composition according to  claim 27 , characterized in that the dose to be administered of the composition is from 75 mg IgM/kg patient to 1 g IgM/kg patient. 
     
     
         34 . The composition according to  claim 33 , characterized in that the composition is administered at least once a week. 
     
     
         35 . The composition according to  claim 27 , characterized in that IgM is recombinant, plasma-derived, cell culture-derived, transgenic, or chemically synthesized. 
     
     
         36 . The composition according to  claim 35 , IgM is plasma-derived IgM, isolated from a suitable fraction of plasma. 
     
     
         37 . The composition according to  claim 27 , characterized in that the composition comprising IgM is administered alone. 
     
     
         38 . The composition according to  claim 27 , characterized in that the composition comprising IgM is administered together with one or more other compositions or molecules selected from anti-inflammatory molecules, small molecule antibiotics, molecules that are antimicrobial in nature, natural or synthetic peptide antimicrobials, proteins with antimicrobial properties, other immunomodulators, or combinations thereof. 
     
     
         39 . The composition according to  claim 38 , characterized in that said other compositions or molecules are vancomycin, meropenem, lactoferrin, or combinations thereof. 
     
     
         40 . A pharmaceutical composition for the treatment of immune complications produced by an infection, comprising:
 a composition suitable for injection comprising immunoglobulin in a pharmaceutically acceptable carrier, wherein the immunoglobulin is at least 90% IgM.   
     
     
         41 . The composition according to  claim 40 , characterized in that the infection is produced by  Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pneumoniae, Clostridium difficile, Clostridium botulinum , or combinations thereof. 
     
     
         42 . The composition according to  claim 40 , characterized in that treatment of immune complications is performed through immunomodulation. 
     
     
         43 . The composition according to  claim 42 , characterized in that immunomodulation is performed through the inhibition of NF-κB induction, through the inhibition of proliferation of peripheral blood mononuclear cells or combination thereof. 
     
     
         44 . (canceled) 
     
     
         45 . The composition according to  claim 40 , characterized in that the composition has a 95% (w/v) of IgM purity. 
     
     
         46 . The composition according to  claim 40 , characterized in that the dose to be administered of the composition is from 75 mg IgM/kg patient to 1 g IgM/kg patient. 
     
     
         47 . The composition according to  claim 46 , characterized in that the composition is administered at least once a week. 
     
     
         48 . The composition according to  claim 40 , characterized in that IgM is recombinant, plasma-derived, cell culture-derived, transgenic, or chemically synthesized. 
     
     
         49 . The composition according to  claim 48 , wherein the IgM is plasma-derived IgM, isolated from a suitable fraction of plasma. 
     
     
         50 . The composition according to  claim 40 , characterized in that the composition comprising IgM is administered alone. 
     
     
         51 . The composition according to  claim 40 , characterized in that the composition comprising IgM is administered together with one or more other compositions or molecules selected from anti-inflammatory molecules, small molecule antibiotics, molecules that are antimicrobial in nature, natural or synthetic peptide antimicrobials, proteins with antimicrobial properties, other immunomodulators, or combinations thereof. 
     
     
         52 . The composition according to  claim 51 , characterized in that said other compositions or molecules are vancomycin, meropenem, lactoferrin, or combinations thereof.